Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer

CONCLUSIONS: Among patients with advanced urothelial cancer treated with EV monotherapy in contemporary practice, EV dosing frequency, and dosage was lower in clinical practice than recommended in the product labeling. Further research is required to understand clinical factors and outcomes associated with the differences observed.PMID:38503592 | DOI:10.1016/j.urolonc.2024.03.001
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Source Type: research